{"product_id":"generic-ruxolitinib-lukedx","title":"RUSODX (Ruxolitinib)","description":"Ruxolitinib is a medication used for the treatment of intermediate or high-risk myelofibrosis,\u003csup id=\"cite_ref-Jakafi_FDA_label_5-1\" class=\"reference\"\u003e\u003c\/sup\u003ea type of myeloproliferative neoplasm that affects the bone marrow; polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; and steroid-refractory acute graft-versus-host disease.\u003csup id=\"cite_ref-Jakafi_FDA_label_5-3\" class=\"reference\"\u003e\u003c\/sup\u003e Ruxolitinib is a Janus kinase inhibitor.\u003csup id=\"cite_ref-Jakafi_FDA_label_5-4\" class=\"reference\"\u003e\u003c\/sup\u003e\u003csup id=\"cite_ref-12\" class=\"reference\"\u003e\u003c\/sup\u003e\r\n\u003ch3\u003eMyelofibrosis\u003c\/h3\u003e\r\nKinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF\r\n\u003ch4\u003eInitial dose\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePlatelet count \u0026gt;200 x10\u003csup\u003e9\u003c\/sup\u003e\/L: 20 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003ePlatelet count 100-200 x10\u003csup\u003e9\u003c\/sup\u003e\/L: 15 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003ePlatelet count 50 to \u0026lt;100 x10\u003csup\u003e9\u003c\/sup\u003e\/L: 5 mg PO BID\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eInsufficient response for patients starting treatment with a platelet count ≥100 X 10^9\/L\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIf response is insufficient and platelet count and ANC are adequate, dose may be increased in 5 mg BID increments; not to exceed 25 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003eDo not increase dose during the first 4 weeks of therapy and no more frequently than q2Weeks\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eConsider dose increases in patients who meet all of the following conditions:\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFailure to achieve a reduction from pretreatment baseline in either palpable spleen length of 50% or a 35% reduction in spleen volume as measured by CT or MRI\u003c\/li\u003e\r\n \t\u003cli\u003ePlatelet count \u0026gt;125 x10\u003csup\u003e9\u003c\/sup\u003e\/L at 4 weeks and never \u0026lt;100 x10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\r\n \t\u003cli\u003eANC levels \u0026gt;0.75 x10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\r\n \t\u003cli\u003eLong-term maintenance at 5 mg BID has not shown responses and limit continued use at this dose to patients in whom the benefits outweigh the potential risks\u003c\/li\u003e\r\n \t\u003cli\u003eDiscontinue if there is no spleen size reduction or symptom improvement after 6 months of therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eInsufficient response for patients starting treatment with a platelet count 50 x 10^9\/L to \u0026lt;100 x 10^9\/L\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIf response is insufficient and platelet count and ANC are adequate, doses may be increased by increments of 5 mg qDay to up to 10 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003eDo not increase dose during the first 4 weeks of therapy and no more frequently than q2Weeks\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eConsider dose increases in patients who meet all of the following conditions:\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePlatelet count has remained at least 40 x 10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\r\n \t\u003cli\u003ePlatelet count has not fallen by \u0026gt;20% in the prior 4 weeks\u003c\/li\u003e\r\n \t\u003cli\u003eANC \u0026gt;1 x 10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\r\n \t\u003cli\u003eNo dose reduction or interruption for an adverse event or hematological toxicity in the prior 4 weeks\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eContinuation of treatment for \u0026gt;6 months should be limited to patients in whom the benefits outweigh the potential risks\u003c\/li\u003e\r\n \t\u003cli\u003eDiscontinue treatment if there is no spleen size reduction or symptom improvement after 6 months of therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003ePolycythemia Vera\u003c\/h3\u003e\r\nIndicated for polycythemia vera in patients who have had an inadequate response to or are intolerant of hydroxyurea\r\n\r\nInitial: 10 mg PO BID\r\n\u003ch4\u003eIncreasing dose for insufficient response\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIf response is insufficient and platelet, hemoglobin, and neutrophil counts are adequate, doses may be increased in 5 mg BID increments to a maximum of 25 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003eDoses should not be increased during the first 4 weeks of therapy and not more frequently than q2Week\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eConsider dose increases in patients who meet all of the following criteria:\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eInadequate efficacy as demonstrated by ≥1 of the following: continued need for phlebotomy, WBC \u0026gt; ULN, platelet count \u0026gt;ULN, palpable spleen that is reduced by \u0026lt;25% from baseline\u003c\/li\u003e\r\n \t\u003cli\u003ePlatelet count ≥140 x10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\r\n \t\u003cli\u003eHemoglobin ≥2 g\/dL\u003c\/li\u003e\r\n \t\u003cli\u003eANC ≥1.5 x 10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eAcute Graft versus Host Disease\u003c\/h3\u003e\r\nIndicated for treatment of steroid-refractory acute graft-versus-host disease (GVHD)\r\n\r\nInitial dose: 5 mg PO BID; may increase to 10 mg BID after at least 3 days if ANC and platelet counts have not decreased by ≥50% compared to baseline\r\n\r\nConsider tapering after 6 months in patients with response who have discontinued therapeutic doses of corticosteroids\r\n\u003ch4\u003eTapering dose\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTaper by 1 dose level ~q8Weeks (eg, 10 mg BID to 5 mg BID to 5 mg qDay)\u003c\/li\u003e\r\n \t\u003cli\u003ePatients unable to tolerate 5 mg qDay: Interrupt treatment until clinical and\/or laboratory parameters recover\u003c\/li\u003e\r\n \t\u003cli\u003eIf acute GVHD signs or symptoms recur during or after taper, consider retreatment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eChronic Graft versus Host Disease\u003c\/h3\u003e\r\nIndicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of 1 or 2 lines of systemic therapy\r\n\r\nInitial dose: 10 mg PO BID\r\n\r\nConsider tapering after 6 months in patients with response who have discontinued therapeutic doses of corticosteroids\r\n\u003ch4\u003eTapering dose\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTaper by 1 dose level ~q8Weeks (eg, 10 mg BID to 5 mg BID, then from 5 mg BID to 5 mg qDay)\u003c\/li\u003e\r\n \t\u003cli\u003eIf acute GVHD signs or symptoms recur during or after taper, consider retreatment\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949575211,"sku":"RL1020230315300","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-05-2668.jpg?v=1787022131","url":"https:\/\/xomeds.com\/products\/generic-ruxolitinib-lukedx","provider":"XOMEDS","version":"1.0","type":"link"}